"The proposed regulations do not explicitly impact the commercial market, although voluntary alignment with Medicare is a possibility, and HHS Secretary Azar has called for follow-up legislation. The regulations also do not change the safe harbor with respect to drugs purchased through Medicare Part B fee-for-service plans, federal rebates collected for Medicaid MCO claims, or federal or supplemental rebates received directly by Medicaid state agencies."  MORE >>